---
title: "Imbruvica (ibrutinib), all indications: Drug interactions questions"
description: "Drug interactions questions on Imbruvica (ibrutinib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Imbruvica have? Which drugs lower Imbruvica levels (strong CYP3A inducers)? Can patients eat grapefruit or Seville oranges while taking Imbruvica? Can Imbruvica be taken with blood thinners (anticoagulants or antiplatelets)? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib), all indications: Drug interactions questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)  
Indication pages: [Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)

## Drug interactions

<a id="imbruvica-drug-interactions"></a>

### What drug interactions does Imbruvica have?

> “7.1 
> Effect of CYP3A Inhibitors on Ibrutinib 
> The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase 
> ibrutinib plasma concentrations [see Clinical Pharmacology (12.3)]. Increased ibrutinib 
> concentrations may increase the risk of drug-related toxicity.  
> Dose modifications of IMBRUVICA are recommended when used concomitantly with 
> posaconazole, voriconazole and moderate CYP3A inhibitors [see Dosage and Administration 
> (2.3)].  
> Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these 
> inhibitors will be used short-term (such as anti-infectives for seven days or less) [see Dosage and 
> Administration (2.3)]. 
> Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or 
> moderate inhibitors of CYP3A. 
> 7.2 
> Effect of CYP3A Inducers on Ibrutinib 
> The coadministration of IMBRUVICA with strong CYP3A inducers may decrease ibrutinib 
> concentrations. Avoid coadministration with strong CYP3A inducers [see Clinical Pharmacology 
> (12.3)].”

Source: [IMBRUVICA: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=30)

> “Effect of Ibrutinib on Substrates of Transporters: In vitro studies suggest that ibrutinib may 
> inhibit BCRP and P-gp transport at clinical doses. The coadministration of oral P-gp or BCRP 
> substrates (e.g., digoxin, methotrexate) with IMBRUVICA may increase their concentrations.”

Source: [IMBRUVICA: Prescribing information, page 37, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=37)

<a id="imbruvica-cyp3a-inducers"></a>

### Which drugs lower Imbruvica levels (strong CYP3A inducers)?

> “The coadministration of IMBRUVICA<sup>®</sup> with strong CYP3A inducers may decrease ibrutinib concentrations. Avoid coadministration with strong CYP3A inducers.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=The%20coadministration%20of,coadministration%20with%20strong%20CYP3A%20inducers.)

> “Examples of strong CYP3A inducers include: apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor, mitotane, phenytoin, rifampin, St. John’s
> wort. Please note that the induction potency of St. John’s wort may vary widely based on preparation.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=Examples%20of%20strong%20CYP3A%20inducers,vary%20widely%20based%20on%20preparation.)

> “Effect of CYP3A Inducers on Ibrutinib: The coadministration of rifampin (strong CYP3A 
> inducer) decreased the Cmax of ibrutinib by more than 13-fold and AUC by more than 10-fold.”

Source: [IMBRUVICA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=36)

<a id="imbruvica-grapefruit"></a>

### Can patients eat grapefruit or Seville oranges while taking Imbruvica?

> “Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or 
> moderate inhibitors of CYP3A.”

Source: [IMBRUVICA: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=30)

<a id="imbruvica-blood-thinners"></a>

### Can Imbruvica be taken with blood thinners (anticoagulants or antiplatelets)?

> “Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA<sup>®</sup> increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients with B-cell malignancies who received IMBRUVICA<sup>®</sup> without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA<sup>®</sup>. Monitor for signs and symptoms of bleeding.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Use%20of%20either%20anticoagulant%20or,signs%20and%20symptoms%20of%20bleeding.)

## Related pages
- [Medical information: Imbruvica (ibrutinib): All indications](https://www.evicenter.com/medical-information/imbruvica)
- [Indication](https://www.evicenter.com/medical-information/imbruvica/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/imbruvica/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/imbruvica/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/imbruvica/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica/access-and-coverage)
